Pharmaceutical sales operations teams often rely on outdated or inaccurate data when prioritizing HCP targets, limiting promotional effectiveness. By applying artificial intelligence and machine learning to real world data, pharmaceutical companies can more effectively target physicians hiding in plain sight and PCPs behaving like specialists.
Specialty and rare diseases have undefined patient populations with patients who are undiagnosed or misdiagnosed, healthcare providers who are unaware of disease states and their manifestations, as well as diagnostic and treatment journeys that are not well-understood. By applying artificial intelligence and machine learning to real world data, pharmaceutical companies can improve outcomes at scale.
This webcast will showcase how rare disease franchises can successfully utilize ML/AI to increase sales velocity, improve patient lifetime value and accelerate time to peak revenue. Attendees will hear how IPM.ai partnered with Kyowa Kirin to implement ML/AI-based patient finding for its X-linked hypophosphatemia (XLH) therapy to uncover undiagnosed patients, better understand the patient treatment journey and trigger highly accurate field intelligence for salesforce optimization. IPM.ai and Kyowa Kirin will share best practices for rare disease businesses seeking to implement ML/AI for optimized commercial and patient outcomes.